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Generalized pustular psoriasis is an unstable inflammatory type of
psoriasis, with widespread areas of erythema and sterile pustules, asso-
ciated with fever and systemic symptoms. Infliximab is a monoclonal
antibody with anti-TNFa activity, approved for use in psoriasis. We
describe a male patient with a long history of stable arthropathic psoria-
sis, hospitalized with a generalized pustular psoriasis and acute exacer-
bation of articular complaints. The disease was resistant to multiple
therapies (acitretin, methotrexate and corticosteroids), so the patient was
started on infliximab, with a very rapid response of both cutaneous and
articular symptoms. He had complete clearing of lesions at week 12, and
marked improvement of the articular symptoms. No recurrence occurred
at 8 months of follow-up with infliximab every 8 weeks. Infliximab had
an extremely rapid therapeutic action response on a recalcitrant gener-
alized pustular psoriasis. The articular response was also excellent, with
significant improvement of quality of life.
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G eneralized pustular psoriasis (Von Zumbuschtype) is an unstable inflammatory type of psoria-sis, with widespread areas of erythema and sterile
pustules, associated with fever and systemic symptoms [1].
In this form of psoriasis, infiltration of the skin with neu-
trophils plays an important role, leading to the characteris-
tic sterile pustules [2]. Infliximab is a monoclonal antibody
with activity against tumour necrosis factor-a (TNF-a),
approved for use in psoriasis [3]. The very rapid onset of
action and reported efficacy makes it an appealing option
for the treatment of generalized pustular psoriasis [4].
Case report
A 59-year-old male patient, with a 24-year history of
plaque psoriasis with moderate articular involvement, was
hospitalized with a severe generalized pustular eruption.
The disease had been stable and localized, with moderate
articular complaints, mostly axial. Betamethasone cream,
calcipotriol ointment and naproxen were the only previous
medication, along with chronic anti-hypertensive therapy
(indapamide, losartan and perindopril).
He developed an inflammatory flare-up of the disease, with
erythematous plaques on the upper trunk, which rapidly
generalized, affecting 90% of the body surface (figure 1).
Small non-follicular pustules developed over these inflam-
matory lesions and fever (38 °C), malaise, and severe
worsening of articular complaints occurred simultaneously,
causing notable difficulty with mobilization.
The patient denied previous use of systemic corticosteroids
or any new medication recently. Infectious and metabolic
triggers were ruled out by clinical and analytical evaluation,
in particular hypocalcemia, streptococcal or human immu-
nodeficiency virus infection. On admission, the patient had
a white blood cell count of 13.4 × 103/lL with 91% neutro-
phils, erythrocyte sedimentation rate of 58 mm and C reac-
tive protein of 23.1 mg/dL.
Treatment was started with methotrexate (15 mg/weekly
PO) and acitretin (35 mg/d), but new pustules and very
severe articular pain continued after three weeks of treat-
ment. As uncontrolled hypertension precluded the use of
cyclosporine, systemic corticosteroids (1 mg/kg/d) were
added, while waiting for the full therapeutic effect of meth-
otrexate and acitretin. There was a rapid resolution of the
pustular eruption, fever and improvement of articular com-
plaints, and slow tapering of corticosteroids was started
(10% weekly dose reduction over 5 weeks). When the dose
reached 0.5 mg/kg/d, new pustules appeared together with
worsening of articular complaints. The corticosteroids
were stopped, and after exclusion of latent tuberculous
infection, infliximab was started at 5 mg/kg IV (weeks 0, 2
and 6, and then every 8 weeks) and both methotrexate and
acitretin were maintained. There was an extremely rapid
response, noticeable from the second day, with complete
clearance of the pustular eruption at the end of the first
week (figure 2). There was also an improvement in both
articular pain and mobility, and methotrexate and acitretin
were stopped at the second infliximab infusion. Complete
clearance of cutaneous lesions was achieved at 12 weeks,
with no significant side effects reported. No relapse was
noted at 26 weeks follow-up, with special emphasis on the
continued articular improvement.
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Discussion
Generalized pustular psoriasis (GPP) is a serious dermato-
logical disease, which can result in significant morbidity
and even mortality [5]. The disease is characterized by
fever, systemic symptoms and generalized pustule forma-
tion on the skin [1].
GPP frequently occurs as an inflammatory flare-up of a
stable psoriasis, often associated with the use of systemic
corticosteroids, and more rarely topical corticosteroids [6,
7]. Many other triggers have been described, like preg-
nancy, hypocalcemia, infections and sudden withdrawal of
anti-psoriatic therapy [8-10]. No infectious, metabolic or
drug-induced trigger was identified in our patient.
Acitretin has good efficacy in pustular psoriasis, with inhi-
bition of neutrophil migration and activation [11]. We com-
bined acitretin and methotrexate for our patient in order to
target both the skin and articular involvement [12]. Sys-
temic corticosteroids were used to rapidly control the in-
flammatory flare of the disease, while waiting for the full
therapeutic effect of methothrexate.
Infliximab has shown good efficacy and very rapid onset of
action for plaque psoriasis and psoriatic arthritis, with a
beneficial impact on quality of life and work productivity
[3, 13-15]. The experience with infliximab in clinical prac-
tice has been expanding, although few reports have been
published on its use in GPP [16-19]. Even in severe recal-
citrant cases, infliximab has been shown to be highly effec-
tive in rapidly controlling the disease [5, 20-22]. By inhib-
iting TNF-a, it appears to downregulate neutrophil-
attractant chemokines which play a relevant role on the
pathogenesis of the disease, such as interleukin-8 (IL-8),
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Figure 1. Generalized pustular psoriasis. A) Multiple active lesions despite combination therapy; B) Rapid improvement after one
week of the first infliximab infusion; C) Complete resolution after 3 infliximab infusions (12 weeks).
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Figure 2. Generalized pustular psoriasis and infliximab therapy: A) Pre-treatment; B) After one week; C) After 12 weeks.
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growth-related oncogene (Gro-a) and monocyte chemoat-
tractant protein (MCP-1) [22].
Our patient had an excellent response to infliximab, with
improvement noticeable from the second day. Complete
clearance of the lesions occurred at week 12, after only
three infusions. This very rapid onset of action has already
been described [20, 21], making it a very attractive therapy
for inpatients, by rapidly and efficiently controlling the
disease and allowing early discharge from hospital [4]. j
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